Ethnic Aspects of Valproic Acid P-Oxidation.

P-oxidation adverse drug reaction biomarker ethnos metabolism metabolite personalized approach pharmacogenetics pharmacokinetics risk factor single-nucleotide variant valproic acid

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
08 May 2024
Historique:
received: 10 04 2024
revised: 29 04 2024
accepted: 03 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

The safety of the use of psychotropic drugs, widely used in neurological and psychiatric practice, is an urgent problem in personalized medicine. This narrative review demonstrated the variability in allelic frequencies of low-functioning and non-functional single nucleotide variants in genes encoding key isoenzymes of valproic acid P-oxidation in the liver across different ethnic/racial groups. The sensitivity and specificity of pharmacogenetic testing panels for predicting the rate of metabolism of valproic acid by P-oxidation can be increased by prioritizing the inclusion of the most common risk allele characteristic of a particular population (country).

Identifiants

pubmed: 38790997
pii: biomedicines12051036
doi: 10.3390/biomedicines12051036
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Natalia A Shnayder (NA)

Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.
Shared Core Facilities "Molecular and Cell Technologies", V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.

Violetta V Grechkina (VV)

Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.

Vera V Trefilova (VV)

Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.

Mikhail Ya Kissin (MY)

Department of Psychiatry and Addiction, I.P. Pavlov First St. Petersburg State Medical University, 197022 Saint Petersburg, Russia.

Ekaterina A Narodova (EA)

Shared Core Facilities "Molecular and Cell Technologies", V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.

Marina M Petrova (MM)

Shared Core Facilities "Molecular and Cell Technologies", V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.

Mustafa Al-Zamil (M)

Department of Physiotherapy, Faculty of Continuing Medical Education, Peoples' Friendship University of Russia, 117198 Moscow, Russia.

Natalia P Garganeeva (NP)

Department of General Medical Practice and Outpatient Therapy, Siberian State Medical University, 634050 Tomsk, Russia.

Regina F Nasyrova (RF)

Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.
International Centre for Education and Research in Neuropsychiatry, Samara State Medical University, 443016 Samara, Russia.

Classifications MeSH